Alberto Bosque
Overview
Explore the profile of Alberto Bosque including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sanz M, Weideman A, Ward A, Clohosey M, Garcia-Recio S, Selitsky S, et al.
bioRxiv
. 2023 Feb;
PMID: 36798291
Antiretroviral therapy (ART) is not curative due to the existence of cellular reservoirs of latent HIV-1 that persist during therapy. Current research efforts to cure HIV-1 infection include "shock and...
12.
Rosenthal J, Premazzi Papa M, Sanz M, Nicholes S, Holmberg C, Bosque A, et al.
Ann Allergy Asthma Immunol
. 2023 Feb;
130(6):743-751.e3.
PMID: 36736722
Background: Clinical trials of the mRNA coronavirus disease 2019 (COVID-19) vaccines excluded individuals with primary antibody deficiencies. Objective: To evaluate whether antibody and T-cell responses to mRNA COVID-19 vaccination in...
13.
Balakrishnan P, Holmberg C, Ledezma D, Bosque A, Fernandes R
Nanomedicine (Lond)
. 2023 Feb;
17(29):2159-2171.
PMID: 36734362
To investigate Prussian blue nanoparticles (PBNPs) coated with the synthetic analog of dsRNA polyinosinic-polycytidylic acid (polyIC) for their ability to function as HIV latency reversing agents. A layer-by-layer method was...
14.
Stevenson E, Terry S, Copertino D, Leyre L, Danesh A, Weiler J, et al.
Nat Commun
. 2022 Aug;
13(1):4888.
PMID: 35985993
Efforts to cure HIV have focused on reactivating latent proviruses to enable elimination by CD8 cytotoxic T-cells. Clinical studies of latency reversing agents (LRA) in antiretroviral therapy (ART)-treated individuals have...
15.
Macedo A, Levinger C, Nguyen B, Richard J, Gupta M, Cruz C, et al.
J Virol
. 2022 Jul;
96(15):e0037222.
PMID: 35867565
Elimination of human immunodeficiency virus (HIV) reservoirs is a critical endpoint to eradicate HIV. One therapeutic intervention against latent HIV is "shock and kill." This strategy is based on the...
16.
Resop R, Bosque A
J Virol
. 2022 Apr;
96(9):e0009622.
PMID: 35412343
Sphingosine-1-phosphate (S1P) is a sphingolipid modulator of a myriad of cellular processes, and therapeutic targeting of S1P signaling is utilized clinically to treat multiple sclerosis. We have previously shown that...
17.
Cheng J, Myers T, Levinger C, Kumar P, Kumar J, Goshu B, et al.
iScience
. 2022 Jan;
25(1):103588.
PMID: 35005538
HIV-specific T cells have diminished effector function and fail to control/eliminate the virus. IL-27, a member of the IL-6/IL-12 cytokine superfamily has been shown to inhibit HIV replication. However, whether...
18.
Bosque A
Methods Mol Biol
. 2022 Jan;
2407:45-55.
PMID: 34985656
Models to study HIV latency have improved our understanding of the mechanisms involved in this process and have helped in the discovery and development of therapeutic strategies to eradicate HIV....
19.
Levinger C, Howard J, Cheng J, Tang P, Joshi A, Catalfamo M, et al.
Sci Rep
. 2021 Dec;
11(1):24455.
PMID: 34934153
No abstract available.
20.
Levinger C, Howard J, Cheng J, Tang P, Joshi A, Catalfamo M, et al.
Sci Rep
. 2021 Dec;
11(1):23682.
PMID: 34880361
Human immunodeficiency virus-1 (HIV-1) persistence in the presence of antiretroviral therapy (ART) has halted the development of curative strategies. Measuring HIV persistence is complex due to the low frequency of...